S&P 500   4,351.85 (+0.50%)
DOW   34,112.23 (+0.12%)
QQQ   361.02 (+0.88%)
AAPL   176.16 (+1.28%)
MSFT   320.20 (+0.21%)
META   303.87 (+2.75%)
GOOGL   131.79 (+1.03%)
AMZN   131.47 (+1.65%)
TSLA   255.05 (-0.25%)
NVDA   419.14 (+2.19%)
NIO   8.56 (+1.30%)
BABA   88.30 (+4.98%)
AMD   97.87 (+1.83%)
T   15.09 (-1.44%)
F   12.60 (+3.28%)
MU   69.12 (+1.80%)
CGC   0.82 (+6.58%)
GE   112.82 (-0.15%)
DIS   82.33 (-0.48%)
AMC   7.92 (+2.86%)
PFE   32.70 (-0.46%)
PYPL   58.65 (+0.05%)
NFLX   383.76 (-0.10%)
S&P 500   4,351.85 (+0.50%)
DOW   34,112.23 (+0.12%)
QQQ   361.02 (+0.88%)
AAPL   176.16 (+1.28%)
MSFT   320.20 (+0.21%)
META   303.87 (+2.75%)
GOOGL   131.79 (+1.03%)
AMZN   131.47 (+1.65%)
TSLA   255.05 (-0.25%)
NVDA   419.14 (+2.19%)
NIO   8.56 (+1.30%)
BABA   88.30 (+4.98%)
AMD   97.87 (+1.83%)
T   15.09 (-1.44%)
F   12.60 (+3.28%)
MU   69.12 (+1.80%)
CGC   0.82 (+6.58%)
GE   112.82 (-0.15%)
DIS   82.33 (-0.48%)
AMC   7.92 (+2.86%)
PFE   32.70 (-0.46%)
PYPL   58.65 (+0.05%)
NFLX   383.76 (-0.10%)
S&P 500   4,351.85 (+0.50%)
DOW   34,112.23 (+0.12%)
QQQ   361.02 (+0.88%)
AAPL   176.16 (+1.28%)
MSFT   320.20 (+0.21%)
META   303.87 (+2.75%)
GOOGL   131.79 (+1.03%)
AMZN   131.47 (+1.65%)
TSLA   255.05 (-0.25%)
NVDA   419.14 (+2.19%)
NIO   8.56 (+1.30%)
BABA   88.30 (+4.98%)
AMD   97.87 (+1.83%)
T   15.09 (-1.44%)
F   12.60 (+3.28%)
MU   69.12 (+1.80%)
CGC   0.82 (+6.58%)
GE   112.82 (-0.15%)
DIS   82.33 (-0.48%)
AMC   7.92 (+2.86%)
PFE   32.70 (-0.46%)
PYPL   58.65 (+0.05%)
NFLX   383.76 (-0.10%)
S&P 500   4,351.85 (+0.50%)
DOW   34,112.23 (+0.12%)
QQQ   361.02 (+0.88%)
AAPL   176.16 (+1.28%)
MSFT   320.20 (+0.21%)
META   303.87 (+2.75%)
GOOGL   131.79 (+1.03%)
AMZN   131.47 (+1.65%)
TSLA   255.05 (-0.25%)
NVDA   419.14 (+2.19%)
NIO   8.56 (+1.30%)
BABA   88.30 (+4.98%)
AMD   97.87 (+1.83%)
T   15.09 (-1.44%)
F   12.60 (+3.28%)
MU   69.12 (+1.80%)
CGC   0.82 (+6.58%)
GE   112.82 (-0.15%)
DIS   82.33 (-0.48%)
AMC   7.92 (+2.86%)
PFE   32.70 (-0.46%)
PYPL   58.65 (+0.05%)
NFLX   383.76 (-0.10%)

Merus (MRUS) Stock Forecast, Price & News

$24.34
-0.47 (-1.89%)
(As of 11:08 AM ET)
Compare
Today's Range
$24.32
$25.08
50-Day Range
$20.13
$27.29
52-Week Range
$12.03
$27.70
Volume
18,647 shs
Average Volume
319,381 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.33

Merus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
78.7% Upside
$44.33 Price Target
Short Interest
Bearish
8.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Merus in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.12) to ($2.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

625th out of 965 stocks

Pharmaceutical Preparations Industry

291st out of 452 stocks


MRUS stock logo

About Merus (NASDAQ:MRUS) Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Price History

MRUS Stock News Headlines

Merus (NASDAQ:MRUS) Given Buy Rating at Needham & Company LLC
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
10 Analysts Have This to Say About Merus
Merus NV (MRUS): A Deep Dive into Its Overvalued Status
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Will Merus (NASDAQ:MRUS) Spend Its Cash Wisely?
H.C. Wainwright Reaffirms Their Buy Rating on Merus (MRUS)
Expert Ratings for Merus
Analyst Expectations for Merus's Future
Merus appoints CFO
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

MRUS Company Calendar

Last Earnings
8/07/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.33
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+78.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-131,190,000.00
Net Margins
-432.68%
Pretax Margin
-428.44%

Debt

Sales & Book Value

Annual Sales
$41.59 million
Book Value
$5.34 per share

Miscellaneous

Free Float
47,715,000
Market Cap
$1.24 billion
Optionable
Not Optionable
Beta
0.84
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 60)
    CEO, Pres & Exec. Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 63)
    CFO & Principal Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 45)
    EVP, Company Sec., COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 56)
    Chief Bus. Officer, Exec. VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 57)
    Chief Medical Officer & Sr. VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 58)
    CTO & Exec. VP
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Sr. VP
  • Ms. Jillian Connell
    VP of Investor Relations & Corp. Communications













MRUS Stock - Frequently Asked Questions

Should I buy or sell Merus stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price forecast for 2023?

10 equities research analysts have issued twelve-month price targets for Merus' stock. Their MRUS share price forecasts range from $35.00 to $49.00. On average, they predict the company's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2023?

Merus' stock was trading at $15.47 at the beginning of the year. Since then, MRUS stock has increased by 60.4% and is now trading at $24.81.
View the best growth stocks for 2023 here
.

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRUS earnings forecast
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) issued its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.20. The biotechnology company earned $10.48 million during the quarter, compared to the consensus estimate of $10.38 million. Merus had a negative net margin of 432.68% and a negative trailing twelve-month return on equity of 69.89%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco NASDAQ Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?
When did Merus IPO?

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by many different retail and institutional investors. Top institutional investors include Commodore Capital LP (8.02%), VR Adviser LLC (3.46%), BVF Inc. IL (3.21%), Franklin Resources Inc. (3.19%), Braidwell LP (3.09%) and BlackRock Inc. (2.38%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends
.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $24.81.

How much money does Merus make?

Merus (NASDAQ:MRUS) has a market capitalization of $1.24 billion and generates $41.59 million in revenue each year. The biotechnology company earns $-131,190,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

How many employees does Merus have?

The company employs 164 workers across the globe.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for the company is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at enquiries@merus.nl.

This page (NASDAQ:MRUS) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -